Alzheimer’s Game Changer: Dual-Action Drug Attacks Disease at Its Core

A new peptide inhibitor, RI-AG03, targets two key areas of the Tau protein in Alzheimer’s disease, showing effectiveness in lab and fruit fly models. This innovative approach could lead to treatments that slow disease progression with minimal side effects. An international team of scientists led by Lancaster University has made a significant breakthrough in the [...]